Featured Jobs
|
Participant Support Representative Daybright Financial
|
|
Retirement Relationship Manager MAP Retirement
|
|
MAP Retirement
|
|
The Pension Source
|
|
Senior Retirement Plan Administrator (TPA) Public Accounting Firm
|
|
Senior Counsel – Investment Solutions Great Gray Trust Company
|
|
MAP Retirement
|
|
Senior Plan Consultant, Defined Benefit DWC - The 401(k) Experts
|
|
Nova 401(k) Associates
|
|
Daybright Financial
|
|
Regional Vice President, Sales MAP Retirement
|
|
Daybright Financial
|
|
MAP Retirement
|
|
The MandMarblestone Group, llc
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
This Old Drug Was Free; Now It's $109,500 a Year
The Washington Post; subscription may be required 
Dec. 19, 2017
"The drug ... was originally approved in 1958 and used primarily to treat the eye disease glaucoma ... [T]he price has been on a roller coaster in recent years -- zooming from a list price of $50 for a bottle of 100 pills in the early 2000s up to $13,650 in 2015, then plummeting back down to free, before skyrocketing back up to $15,001 after a new company, Strongbridge Biopharma, acquired the drug and relaunched it this spring."
|
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |